Article
Oncology
Chengcheng Gong, Qin Xiao, Yi Li, Yajia Gu, Jian Zhang, Leiping Wang, Jun Cao, Zhonghua Tao, Yannan Zhao, Yizhao Xie, Xichun Hu, Biyun Wang
Summary: The study revealed that ERP occurred in more than half of patients with metastatic breast cancer treated with everolimus, and was associated with improved treatment outcomes.
Article
Medicine, General & Internal
Sebastian Wolf, Verena S. Hoffmann, Florian Sommer, Matthias Schrempf, Mingming Li, Martin Ryll, Ulrich Wirth, Matthias Ilmer, Jens Werner, Joachim Andrassy
Summary: Based on network meta-analysis, ERL combined with CNI showed the strongest anti-CMV effect compared to regular CNI treatment (RR 0.27, CI 0.22-0.32, p <0.0001).
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Ho Joong Choi, Jung Hyun Park, Ok-Hee Kim, Kee-Hwan Kim, Ha Eun Hong, Haeyeon Seo, Say-June Kim
Summary: Combining everolimus with Ku0063794 in the treatment of patients with hepatocellular carcinoma can significantly reduce cell viability, increase apoptosis, and decrease autophagy, showing potentiated anticancer effects.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Surgery
Sunbin Ling, Qifan Zhan, Guangjiang Jiang, Qiaonan Shan, Lu Yin, Rui Wang, Qingyang Que, Xuyong Wei, Shengjun Xu, Jiongjie Yu, Wei Zhou, Lincheng Zhang, Jiaqi Bao, Qianwei Ye, Renyi Su, Rongli Wei, Jimin Liu, Kangchen Chen, Jingrui Wang, Haiyang Xie, Shusen Zheng, Xin He, Jiajia Xiang, Xiao Xu
Summary: This study discovered that E2F7 gene induces and promotes resistance to mTOR inhibitor sirolimus in HCC under hypoxic conditions. This is achieved by suppressing mTOR complex 1 and activating hypoxia-inducible factor-1 alpha and its downstream genes. Low expression of E2F7 can serve as an effective biomarker for predicting the response to anti-mTOR-based therapies after LT in HCC patients. Targeting E2F7 synergistically inhibits HCC growth with sirolimus.
AMERICAN JOURNAL OF TRANSPLANTATION
(2022)
Article
Oncology
Mariarosaria Negri, Feliciana Amatrudo, Annalisa Gentile, Roberta Patalano, Tatiana Monto, Cristina de Angelis, Chiara Simeoli, Rosa Pirchio, Renata Simona Auriemma, Annamaria Colao, Rosario Pivonello, Claudia Pivonello
Summary: The study found that exosomes from EveR cells could induce drug resistance to EVE in HCC cells, while VitD could reverse exosome-induced EVE resistance by resensitizing HCC cells to EVE treatment.
FRONTIERS IN ONCOLOGY
(2022)
Article
Surgery
Thomas J. Wert, Stephanie Heeney, Maddy Morrison
Summary: This study aimed to evaluate the concentration/dose ratio for conversion between two mTOR inhibitors in heart transplant patients. The results showed that conversion between the two agents improved tolerability and did not lead to significant changes in measured lab values.
CLINICAL TRANSPLANTATION
(2023)
Article
Biochemistry & Molecular Biology
Johannes Zellmer, Hsi-Yu Yen, Lena Kaiser, Franz Josef Gildehaus, Guido Boening, Katja Steiger, Marcus Hacker, Peter Bartenstein, Andrei Todica, Alexander R. Haug, Harun Ilhan
Summary: This study investigated the synergistic and potentially enhanced efficacy of combined treatment with everolimus and [177Lu]Lu-DOTA-TATE in a mouse model of advanced pancreatic neuroendocrine tumors (pNETs). The results showed that PRRT significantly inhibited tumor growth, but the addition of everolimus did not further enhance the efficacy.
Article
Oncology
Brian M. Slomovitz, Virginia L. Filiaci, Joan L. Walker, Michael C. Taub, Karen A. Finkelstein, John W. Moroney, Aimee C. Fleury, Carolyn Y. Muller, Laura L. Holman, Larry J. Copeland, David S. Miller, Robert L. Coleman
Summary: This study evaluated the efficacy and tolerability of everolimus/letrozole and medroxyprogesterone acetate/tamoxifen in the treatment of metastatic endometrial carcinoma. The results showed that both treatment regimens demonstrated clinically meaningful efficacy in patients, especially in chemotherapy-naive patients.
GYNECOLOGIC ONCOLOGY
(2022)
Article
Oncology
Maria Spiliotaki, Galatea Kallergi, Christos Nikolaou, Nikolaos Xenidis, Eleni Politaki, Stella Apostolaki, Nefeli Georgoulia, Filippos Koinis, Nikolaos Tsoukalas, Dora Hatzidaki, Athanasios Kotsakis, Vassilis Georgoulias
Summary: The study demonstrates that the combination of E/E treatment can lead to early elimination of proliferating CTCs in mBC patients, which is associated with a favorable clinical outcome.
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2021)
Article
Clinical Neurology
Katarzyna Bobeff, Karolina Krajewska, Dobromila Baranska, Katarzyna Kotulska, Sergiusz Jozwiak, Wojciech Mlynarski, Joanna Trelinska
Summary: The study indicates that maintenance therapy with everolimus may be an effective therapeutic option for patients with tuberous sclerosis and subependymal giant cell astrocytoma, providing a certain level of efficacy and safety, stabilizing the condition, and with a lower frequency of adverse events during maintenance therapy. It is recommended to carefully monitor for possible disease progression during maintenance therapy, especially in the first six months.
FRONTIERS IN NEUROLOGY
(2021)
Review
Biochemistry & Molecular Biology
Shilpi Singh, Debashis Barik, Karl Lawrie, Iteeshree Mohapatra, Sujata Prasad, Afsar R. Naqvi, Amar Singh, Gatikrushna Singh
Summary: The mTOR signaling pathway plays a crucial role in glioblastoma, but inhibiting it poses challenges. This article discusses potential targets and strategies for mTOR inhibitor development, as well as optimized drug delivery systems and personalized treatment approaches.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Chemistry, Medicinal
Mingfeng Yu, Theodosia Teo, Yuchao Yang, Manjun Li, Yi Long, Stephen Philip, Benjamin Noll, Gary K. Heinemann, Sarah Diab, Preethi Eldi, Laychiluh Mekonnen, Abel T. Anshabo, Muhammed H. Rahaman, Robert Milne, John D. Hayball, Shudong Wang
Summary: CDK8 plays a crucial role in transcriptional regulation and its dysregulation is associated with various types of cancer. Inhibition of CDK8 with compound 38 showed potent anti-proliferative effects on acute myeloid leukaemia cells without systemic toxicity in preclinical studies. Further research on compound 38 as an anticancer agent is warranted.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Article
Pharmacology & Pharmacy
Camille Moreau-Bachelard, Marie Robert, Carole Gourmelon, Emmanuelle Bourbouloux, Anne Patsouris, Jean-Sebastien Frenel, Mario Campone
Summary: Everolimus is an oral drug that inhibits mTOR with immunosuppressive and antiproliferative characteristics. It is commonly used in association with exemestane in hormone receptor (HR)-positive advanced breast cancer (ABC). This review summarizes the publications relating to everolimus in breast cancer and highlights its efficacy and tolerability, particularly in patients who have previously been treated with aromatase inhibitors (AI).
EXPERT OPINION ON PHARMACOTHERAPY
(2023)
Article
Oncology
Eddy S. Yang, Amin H. Nassar, Elio Adib, Opeyemi A. Jegede, Sarah Abou Alaiwi, Deborah L. Della Manna, David A. Braun, Mahsa Zarei, Heng Du, Sumanta K. Pal, Gurudatta Naik, Guru P. Sonpavde
Summary: The study investigated the relationship between gene expression and treatment benefit of Everolimus in metastatic renal cell carcinoma patients. Specific gene signatures were identified that could potentially predict the response to Everolimus monotherapy or combination therapy with a vascular disrupting agent. Further validation of these gene signatures is needed to determine their clinical utility in patient selection.
MOLECULAR CANCER THERAPEUTICS
(2021)
Review
Oncology
Qian Luo, Ruijuan Du, Wenting Liu, Guojing Huang, Zigang Dong, Xiang Li
Summary: Esophageal squamous cell carcinoma (ESCC) is the most common type of esophageal cancer worldwide, mainly occurring in specific regions of Asia. The PI3K/Akt/mTOR signaling pathway plays a crucial role in regulating cell growth, differentiation, migration, metabolism, and proliferation, and is closely associated with survival and prognosis in ESCC patients. Many molecules can regulate this pathway and lead to its aberrant activation. Several effective inhibitors of the PI3K/Akt/mTOR pathway have been developed.
FRONTIERS IN ONCOLOGY
(2022)
